Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34693
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18055/20253 (89%)
造访人次 : 25165678      在线人数 : 533
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34693


    標題: No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
    作者: Kang, Nai-Wen
    Kuo, Yu-Hsuan
    Wu, Hung-Chang
    Ho, Chung-Han
    Chen, Yi-Chen
    Yang, Ching-Chieh
    貢獻者: Chi Mei Hospital
    Department of Cosmetic Science, Chia Nan University of Pharmacy & Science
    Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science
    Chi Mei Hospital
    Southern Taiwan University of Science & Technology
    Department of Pharmacy, Chia Nan University of Pharmacy & Science
    關鍵字: concurrent chemoradiotherapy
    mucoepidermoid carcinoma
    neck-cancer
    head
    radiotherapy
    management
    cisplatin
    outcomes
    tumors
    日期: 2022
    上傳時間: 2023-12-11 14:05:28 (UTC+8)
    出版者: NATURE PORTFOLIO
    摘要: This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009-2017) with advanced (T3-4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan-Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p=0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72-1.23) and DSS (aHR 0.96; 95% CI 0.72-1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection.
    關聯: SCIENTIFIC REPORTS, v.12, Article number: 20862
    显示于类别:[化妝品應用與管理系(所)] 期刊論文
    [醫務管理系(所)] 期刊論文
    [藥學系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML104检视/开启
    s41598-022-25468-9.pdf1255KbAdobe PDF14检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈